Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Status:
Completed
Trial end date:
2017-10-02
Target enrollment:
Participant gender:
Summary
Phase 2, open-label, non-randomized, monotherapy study to evaluate the safety and efficacy of
ibrutinib in subject with relapsed/refractory Marginal Zone Lymphoma (MZL).